Validation of the Patient Care Monitor (Version 2.0): A Review of System Assessment Instrument for Cancer Patients

被引:75
作者
Abernethy, Amy P. [1 ,2 ]
Zafar, Syed Yousuf [1 ,2 ]
Uronis, Hope [1 ]
Wheeler, Jane L. [1 ]
Coan, April [2 ]
Rowe, Krista [1 ]
Shelby, Rebecca A. [3 ]
Fowler, Robin [1 ]
Herndon, James E., II [2 ,4 ]
机构
[1] Duke Univ, Med Ctr, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Med, Duke Comprehens Canc Ctr, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA
[4] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA
关键词
Patient-reported outcomes; electronic surveys; survey validation; cancer symptoms; QUALITY-OF-LIFE; FUNCTIONAL ASSESSMENT; REPORTED OUTCOMES; ONCOLOGY PRACTICE; THERAPY; COMPUTER; RELIABILITY; VALIDITY; PAPER; QUESTIONNAIRES;
D O I
10.1016/j.jpainsymman.2010.01.017
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. The Patient Care Monitor (PCM) is a review of systems survey delivered by means of an electronic patient-reported outcomes (ePRO) data capture system that uses wireless tablet computers. Although the PCM 1.0 is validated, the updated PCM 2.0 has not been validated nor tested in the academic setting. Objectives. To validate and test the PCM 2.0 in three cancer populations. Methods. Two hundred seventy-five individuals participated in three clinical trials enrolling breast (n = 65), gastrointestinal (n = 113), and lung (n = 97) cancer patients. Internal consistency was evaluated using Cronbach's alpha coefficients calculated for six PCM subscales (general physical symptoms, treatment side effects, distress, despair, impaired performance, and impaired ambulation) and a Quality-of-Life Index. Construct validity was evaluated through Pearson's correlation between PCM subscales and subscales of the Functional Assessment of Cancer Therapy General (FACT-G), the M.D. Anderson Symptom Inventory (MDASI), and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). The participants had the following characteristics: mean age was 58 years (standard deviation: 11), 52% were females, 79% were whites, 17% were blacks, 62% had no college degree, and 78% had metastatic or recurrent disease. Results. Raw and normalized scores for PCM 2.0 subscales were internally consistent across study cohorts. PCM 2.0 subscales correlated significantly (P < 0.05) with the corresponding subscales on FACT-G, MDASI, and FACIT-F, with the exception of FACT-G social well-being, particularly for the lung cancer population. These correlations demonstrated construct validity. PCM 2.0 results followed expected patterns by cancer etiology. Prior reports demonstrate patient satisfaction with PCM 2.0. Conclusion. Within three unique academic oncology populations, PCM 2.0 is a valid ePRO instrument for assessing symptoms with seven patient-centered subscale or index domains. J Pain Symptom Manage 2010;40:545-558. (C) 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:545 / 558
页数:14
相关论文
共 32 条
[1]   Improving Health Care Efficiency and Quality Using Tablet Personal Computers to Collect Research-Quality, Patient-Reported Data [J].
Abernethy, Amy P. ;
Herndon, James E., II ;
Wheeler, Jane L. ;
Patwardhan, Meenal ;
Shaw, Heather ;
Lyerly, H. Kim ;
Weinfurt, Kevin .
HEALTH SERVICES RESEARCH, 2008, 43 (06) :1975-1991
[2]   Feasibility and Acceptability to Patients of a Longitudinal System for Evaluating Cancer-Related Symptoms and Quality of Life: Pilot Study of an e/Tablet Data-Collection System in Academic Oncology [J].
Abernethy, Amy P. ;
Herndon, James E. ;
Wheeler, Jane L. ;
Day, Jeannette M. ;
Hood, Linda ;
Patwardhan, Meenal ;
Shaw, Heather ;
Lyerly, Herbert Kim .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2009, 37 (06) :1027-1038
[3]   Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities [J].
Basch, Ethan ;
Artz, David ;
Iasonos, Alexia ;
Speakman, John ;
Shannon, Kevin ;
Lin, Kai ;
Pun, Charmaine ;
Yong, Henry ;
Paul, Fearn ;
Barz, Allison ;
Scher, Howard I. ;
McCabe, Mary ;
Schrag, Deborah .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2007, 14 (03) :264-268
[4]   Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument [J].
Brady, MJ ;
Cella, DF ;
Mo, F ;
Bonomi, AE ;
Tulsky, DS ;
Lloyd, SR ;
Deasy, S ;
Cobleigh, M ;
Shiomoto, G .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :974-986
[5]  
CALHOUN E, 2000, P AM SOC CLIN ONCOL, V19
[6]  
CELLA D, 1997, P AM SOC CLIN ONCOL, V16
[7]   RELIABILITY AND VALIDITY OF THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY - LUNG (FACT-L) QUALITY-OF-LIFE INSTRUMENT [J].
CELLA, DF ;
BONOMI, AE ;
LLOYD, SR ;
TULSKY, DS ;
KAPLAN, E ;
BONOMI, P .
LUNG CANCER, 1995, 12 (03) :199-220
[8]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[9]  
Cleeland CS, 2000, CANCER-AM CANCER SOC, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO
[10]  
2-V